Attached files
| file | filename |
|---|---|
| EX-10.13 - EX-10.13 - NUTRACEUTICAL INTERNATIONAL CORP | a14-23764_1ex10d13.htm |
| EX-99.1 - EX-99.1 - NUTRACEUTICAL INTERNATIONAL CORP | a14-23764_1ex99d1.htm |
| EX-10.12 - EX-10.12 - NUTRACEUTICAL INTERNATIONAL CORP | a14-23764_1ex10d12.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2014
NUTRACEUTICAL INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-23731 |
|
87-0515089 |
|
(State of incorporation) |
|
(Commission |
|
(IRS Employer |
|
1400 Kearns Boulevard, 2nd Floor |
|
|
|
Park City, Utah |
|
84060 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (435) 655-6106
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On November 4, 2014, Nutraceutical International Corporation closed on an amended revolving credit facility, with Rabobank International continuing as lead bank under the facility. Wells Fargo will also remain as a lender and is currently Nutraceutical’s primary US commercial banking partner. This amended credit facility extends the term of the line of credit to November 2019, increases the ongoing commitment from $90 million to $100 million and provides an additional accordion feature to increase the commitment up to $130 million, subject to certain conditions.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit |
|
|
|
Number |
|
Description |
|
|
|
|
|
10.12 |
|
Second Amendment Agreement dated as of November 4, 2014 among Nutraceutical and its lenders |
|
10.13 |
|
Annex I to Second Amendment Agreement |
|
99.1 |
|
Press Release issued by Nutraceutical dated November 5, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
NUTRACEUTICAL INTERNATIONAL CORPORATION | |
|
|
| |
|
|
By: |
/s/ Cory J. McQueen |
|
Date: November 5, 2014 |
|
|
|
|
|
Cory J. McQueen |
|
|
|
Vice President and Chief Financial Officer |
|
|
|
(Principal Financial and Accounting Officer) |